Back to top
more

Tetraphase Pharmaceuticals, Inc. (TTPH)

(Delayed Data from NSDQ)

$1.06 USD

1.06
371,156

+0.07 (7.07%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.

Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tetraphase (TTPH) delivered earnings and revenue surprises of 19.63% and -28.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?

by Zacks Equity Research

During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.

Tetraphase Pharmaceuticals (TTPH) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tetraphase (TTPH) delivered earnings and revenue surprises of 4.31% and 115.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Tetraphase Pharmaceuticals (TTPH) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tetraphase (TTPH) delivered earnings and revenue surprises of -10.53% and -49.62%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Tetraphase Pharmaceuticals (TTPH) Q2 Earnings Expected to Decline

by Zacks Equity Research

Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tetraphase (TTPH) delivered earnings and revenue surprises of 7.69% and -34.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tetraphase (TTPH) delivered earnings and revenue surprises of -5.71% and -44.93%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Tetraphase Pharmaceuticals (TTPH) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research

Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Options Traders Expect Huge Moves in Tetraphase (TTPH) Stock

by Zacks Equity Research

Investors need to pay close attention to Tetraphase (TTPH) stock based on the movements in the options market lately.

    Implied Volatility Surging for Tetraphase (TTPH) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Tetraphase (TTPH) stock based on the movements in the options market lately.

      Tetraphase Pharmaceuticals (TTPH) Reports Q2 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      Tetraphase (TTPH) delivered earnings and revenue surprises of 50.00% and 418.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Options Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock

        by Zacks Equity Research

        Investors in Tetraphase Pharmaceuticals (TTPH) need to pay close attention to the stock based on moves in the options market lately.

          Options Traders Expect Huge Moves in Tetraphase Pharmaceuticals (TTPH) Stock

          by Zacks Equity Research

          Tetraphase Pharmaceuticals (TTPH) needs Investors to pay close attention to the stock based on moves in the options market lately.

            Are Options Traders Betting on a Big Move in Tetraphase Pharmaceuticals (TTPH) Stock?

            by Zacks Equity Research

            Investors in Tetraphase Pharmaceuticals (TTPH) need to pay close attention to the stock based on moves in the options market lately.

              Implied Volatility Surging for Tetraphase Pharmaceuticals (TTPH) Stock Options

              by Zacks Equity Research

              Investors in Tetraphase Pharmaceuticals, Inc. (TTPH) need to pay close attention to the stock based on moves in the options market lately.

                Implied Volatility Surging for Tetraphase Pharmaceuticals (TTPH) Stock Options

                by Zacks Equity Research

                Huge implied volatility makes Tetraphase Pharmaceuticals (TTPH) Stock lucrative to the option traders.

                  Are Options Traders Betting on a Big Move in Tetraphase (TTPH) Stock?

                  by Zacks Equity Research

                  Tetraphase (TTPH) Stock's substantial implied volatility might attract the option traders.